Core Viewpoint - Fosun Pharma (600196)(02196) plans to adopt a restricted share unit scheme for H-shares in 2025, aiming to incentivize employees through equity participation [1] Summary by Relevant Sections Share Grant Details - The company intends to grant a total of 10.6964 million restricted share units to 201 eligible employees upon the adoption of the plan, with the specific grant date to be determined by the board [1] - The eligible employees can purchase the corresponding number of H-shares at a price of RMB 1.00 per unit after the restricted share units vest [1] Limitations and Allocations - Due to the cap set by the Hong Kong Stock Exchange on H-share plans, the maximum number of restricted share units that can be granted under this plan is 13.3705 million, which corresponds to 13.3705 million H-shares [1] - This represents approximately 0.5007% of the company's total shares and about 2.4716% of the total H-shares (excluding treasury shares) [1]

Summary of the News Article Core Viewpoint The article discusses Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s plan to adopt a restricted share unit scheme for H shares in 2025, aimed at enhancing corporate governance and retaining talent through equity incentives. Group 1: Overview of the Plan - The company plans to implement a 2025 H share restricted share unit scheme to improve corporate governance and establish a long-term incentive mechanism [3][8]. - The total number of restricted share units to be granted under this plan is 13,370,500, which represents approximately 0.5007% of the company's total shares [2][8]. - The initial grant will consist of 10,696,400 restricted share units, accounting for 80% of the total plan [2][8]. Group 2: Details of the Initial Grant - The initial grant will be awarded to 201 eligible employees at a price of RMB 1.00 per unit after the units vest [2][6]. - The total number of shares available for the initial grant represents about 0.4005% of the company's total shares [2][8]. - The plan requires approval from the company's shareholders and the shareholders of its indirect controlling shareholder, Fosun International Limited, before implementation [3][7]. Group 3: Eligibility and Conditions - Eligible employees include executive directors, employee directors, senior management, and other key personnel deemed necessary for motivation [9]. - The plan's effectiveness is contingent upon shareholder approval and compliance with relevant laws and regulations [8][9]. - The vesting schedule for the initial grant is structured over three years, with 33% vesting after 12 months, another 33% after 24 months, and the final 34% after 36 months [17][18]. Group 4: Performance Assessment - The performance assessment for the group will focus on two key indicators: net profit attributable to shareholders and revenue from innovative drugs [20][21]. - The targets for these indicators are set for the upcoming years, with specific financial goals outlined for each assessment period [21][22]. - If the performance metrics are not met, the corresponding restricted share units may not vest [24].